983 results about "Disaccharide" patented technology

Methods are described for converting carbohydrates including, e.g., monosaccharides, disaccharides, and polysaccharides in ionic liquids to value-added chemicals including furans, useful as chemical intermediates and/or feedstocks. Fructose is converted to 5-hydroxylmethylfurfural (HMF) in the presence of metal halide and acid catalysts. Glucose is effectively converted to HMF in the presence of chromium chloride catalysts. Yields of up to about 70% are achieved with low levels of impurities such as levulinic acid.

This invention relates to formulations and methods for preserving sensitive biologicals, viruses, bacteria and eukaryotic cells by drying. More particularly, the invention relates to preservation mixtures containing viruses or cells and protectants, including a combination of a methylated monosaccharide and a disaccharide, or oligosaccharide, wherein the mixtures are adapted to stabilize these during dehydration and subsequent storage at ambient and higher temperature.

Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrins (BPD) having light absorption maxima in the range of 670-780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.

A process for lyophilization or freeze-drying of a pharmaceutical product is provided and a liquid formulation suitable for lyophilization. In particular, a process for lyophilization or freeze-drying a liquid formulation that includes a protein active agent, a bulking agent and a saccharide stabilizing agent is provided. The saccharide to bulking agent ratio and the protein concentration of the formulation are important factors that affect crystallization of the bulking agent during lyophilization and storage as are some processing conditions. In one embodiment, the saccharide is a disaccharide, such as sucrose and the crystalline bulking agent is mannitol. The protein can be an antibody or a non-antibody protein.

A delicious candy in which crystallized xylitol has been molded in a desired shape and which has a beautiful shape and gives a cooling feeling attributable to xylitol; and a process by which the candy can be easily and industrially continuously produced. The novel candy (1) has a layered constitution which comprises two opposed candy part layers (3) and, sandwiched between these, a xylitol crystal part layer (2) comprising xylitol as the main component, at least one ingredient selected among monosaccharides, disaccharides, and sugar alcohols obtained by reducing these, and a viscosity-lowering agent as essential components, the at least one ingredient and the viscosity-lowering agent being contained in given amounts based on the xylitol as the main component.

Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrine (BPD) having light absorption maxima in the range of 670-780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.

The invention relates to a vaccine composition comprising:

• a) inactivated whole virus, and
• b) a stabilizing excipient which comprises:
  • i. a buffer solution,
  • ii. a mixture of essential and nonessential amino acids,
  • iii. a disaccharide,
  • iv. a polyol,
  • v. a chelating agent,
  • vi. urea or a urea derivative, and
  • vii. a nonionic surfactant.

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

New hair styling compositions are described that use monosaccharides and/or disaccharides instead of synthetic fixative polymers or copolymers to provide excellent hold to hair without flaking.

The invention relates to a qualitative and quantitative analysis method for polyoses, which comprises the following steps: (1) the zymohydrolysis and the verification of the polyoses: measuring the content of a polyoses water solution by a colorimetric method; (2) comparing the change of a polyoses mapping before and after zymohydrolysis by HPSEC-ELSD analysis; (3) saccharide ingredient direct HPLC analysis of a polyoses zymohydrolysis solution or HPLC analysis after pre-column derivatization: identifying polyoses mapping and chromatogram peaks by taking a standard monosaccharose, a uronic acid, a disaccharide, and the like as contrasts and taking a chromatogram peak mass-to-charge ratio as reference, and using stable characteristic sections as a quantitative analysis index; and (4) realizing the qualitative and quantitative analysis of the polyoses by establishing polyoses zymohydrolysis responding characteristics and polyoses zymohydrolysis mapping which are based on structural information through the independent or combining application of the steps. The qualitative and quantitative analysis method can be used for the identification and quantitative measurement of the polyoses of traditional Chinese medicine, such as panax, panax pseudoginseng, gen-seng, aweto, cordyceps, ganoderma lucidum, fomes japonica, milk veteh, angelica, and the like and provides an effective method for controlling the quality of the polyoses and the products thereof.

The invention discloses a special gestation compound feed for sows at later stage of pregnancy. The special gestation compound feed is prepared from the following raw materials: corn, bran, rice bran meal, DDGS (dried distiller grains with soluble), swelling soya dregs, swelling soybean flour, fermented soybean meal, compound sugar, mountain flour, calcium hydrogen phosphate, choline chloride, common salt, compound premix, L-lysine hydrochloride, L-threonine, acidifier, clostridium butyricum and yeast cell wall polysaccharides. The invention, starts from nutrition of the sows at the later stage of the pregnancy, gives consideration to the growth of fetuses and the physiological characteristics of the sows per se, designs daily ration with high protein, high amino acid and low energy, adds the compound sugar constituted by different monosaccharides and disaccharides, and can provide energy which can be utilized quickly and improve the birth weight and the uniformity of piglets; and by adding the clostridium butyricum and the yeast cell wall polysaccharides, the special gestation compound feed can improve the intestinal health of the sows, improve immunity, regulate intestinal peristalsis, reduce the constipation incidence of the sows, shorten the labor stage of the sows, reduce the incidence rate of mastitis and endometritis of the sows, and assist the sows in rapid postpartum recovery.

Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF- alpha ) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF- alpha . The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.

A process for reducing the monosaccharide and/or disaccharide content in a food material, the process comprising contacting the food material with a glucosyltransferase that comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1.

It has been discovered that biodegradable and non-toxic chelant compositions can perform multiple beneficial functions in an aqueous fracturing fluid through the chelation of ions. Some of the multiple functions include various combinations of the following: demulsifier, demulsifier enhancer, scale inhibitor, crosslink delay agent, crosslinked gel stabilizer, enzyme breaker stabilizer, and the like. Some of the chelants used in the compositions include, but are not necessarily limited to, sodium polyaspartate; sodium iminodisuccinate; disodium hydroxyethyleneiminodiacetate (Na₂HEIDA); sodium gluconate; sodium glucoheptonate; sugar alcohols; monosaccharides; disaccharides; and mixtures thereof.

The invention relates to a composition for coating a frozen confection, the composition comprising 10 to 50 wt. % dry glucose syrup with a DE (Dextrose Equivalent) below 40, and a total amount of mono and di-saccharides below 10 wt. %, and a water activity below 1.0 and 35 to 70 wt. % fat. The invention also relates to a process for making the composition.

The embodiments relate to fat emulsion structures based on both an aqueous and non-aqueous glycerin component as the primary aqueous component in which the fat emulsion can create a wide range of viscosities that mimic fat structures similar to cream, or all the way to hardened fat structures like Trans Fat. The fat emulsion can be added to a wide group of foods that use a monosaccharide or disaccharide as the basis for its sweetener component, can lower the sugar content of foods, can improve mouth feel while lowering the fat content in high fat foods, can add a balance of dietary fats and fiber to foods, and can add antioxidant content to food products.

The invention relates to a cross-linked hyaluronic acid cell-scaffold material and its preparation method and application. The cross-linked hyaluronic acid cell-scaffold material is obtained by crosslinking of high-molecular hyaluronate and low-molecular hyaluronate. The proportion of hyaluronate disaccharide molecules which take part in the crosslinking is 0.5%-20%, and expansion rate of the hyaluronate disaccharide molecules in an isotonic solution is 80%-110%. The preparation method of the cell-scaffold material comprises two freeze drying steps. Hyaluronate mixed with a cross-linking agent is formed firstly; after a heating reaction, water is added for swelling to form gel; and freeze drying is then carried out to obtain the porous scaffold material. The scaffold has abundant pores, has a certain mechanical strength and pore size and has good hydroscopicity and biocompatibility. The scaffold can be used as a tissue engineering cell-scaffold in promoting cartilage injury repairing and also can be used for preparing a haemostasis anti-adhesion material.

The invention provides a feeding combination for brooding layers before six-week old, which includes a feeding I for layers before two-week old and a feeding II for layers between three to six-week old, wherein the feeding I comprises corn, puffed grains, puffed soybean meal, puffed soybeans, fermented soybean meal, insect protein, one level steam fish meal, plant oil, monosaccharide or disaccharides, calcium hydrogen phosphate, limestone powder, baking soda, compound trace elements, amino acid, choline chloride, salt, anti-stress agent, multi-vitamin, compound enzyme preparation and phytase raw materials; and the feeding II comprises corn, soybean meal, fermented soybean meal, puffed soybeans, insect protein, one level steam fish meal, plant oil, monosaccharide or disaccharides, calcium hydrogen phosphate, limestone powder, baking soda, compound trace elements, amino acid, choline chloride, salt, anti-stress agent, multi-vitamin, compound enzyme preparation and phytase. Compared with the existing layer feeding, the phase combination feeding is more reasonable and scientific, and the immunity and the survive rate of layers are obviously improved and the morbidity is obviously decreased.

The present invention relates to an ophthalmic solution comprising 0.00001 to 10.0 weight percent of a simple saccharide, at least 0.00001 weight percent of a preservative, and not more than about 0.2 percent by weight chloride. The simple saccharide is chosen from the group consisting of: inositol; mannitol; sorbitol; sucrose; dextrose; glycerin; propylene glycol; ribose; triose; tetrose; erythrose; threose; pentose; arabinose; ribulose; xylose; xylulose; lyxose; hexose; allose; altrose; fructose; galactose; glucose; gulose; idose; mannose; sorbose; talose; tagatose; adlose; ketose; heptose; sedoheptulose; monosaccharides; disaccharides; sugar alcohols; xylitol; and polyol.

The invention discloses a preparation method of a multistage porous carbon material. The preparation method comprises the following steps: blending a carbon source with an activator, and performing two-step carbonization and after treatment to obtain the multistage porous carbon material, wherein the two-step carbonization comprises low-temperature carbonization and high-temperature carbonization, the temperature of the low-temperature carbonization is 200-400 DEG C, and the temperature for the high-temperature carbonization is 800-1200 DEG C; the carbon source is a biomass, monosaccharide, disaccharide or polysaccharide of which the cellulose content is more than 20%; and the activator is selected from ammonium oxalate, potassium oxalate, potassium hydrogen oxalate, potassium tetroxalate, sodium oxalate, sodium hydrogen oxalate, sodium tetroxalate, sodium hydrogen carbonate or potassium hydrogen carbonate. The invention provides the preparation method of the multistage porous carbon material rich in macropore, and according to the preparation method, physical expansion and chemical activation are utilized, and a carbon source is used as a raw material to match with a specific activator in order to prepare the multistage porous carbon material rich in macropore; and the raw material is low in price and easy to obtain, the method is simple and strong in sustainability and has a potential for large-scale production.

The subject of the invention is superparamagnetic nanoparticle probes based on iron oxides, to advantage magnetite or maghemite, with modified surface, coated with mono-, di- or polysaccharides from the group including D-arabinose, D-glucose, D-galactose, D-mannose, lactose, maltose, dextrans and dextrins, or with amino acids or poly(amino acid)s from the group including alanine, glycine, glutamine, asparagine, histidine, arginine, L-lysine, aspartic and glutamic acid or with synthetic polymers based on (meth)acrylic acid and their derivatives selected from the group containing poly(N,N-dimethylacrylamide), poly(N,N-dimethylmethacrylamide), poly(N,N-diethylacrylamide), poly(N,N-diethylmethacrylamide), poly(N-isopropylacrylamide), poly(N-isopropylmethacrylamide), which form a colloid consisting of particles with narrow distribution with polydispersity index smaller than 1.3, the average size of which amounts to 0.5-30 nm, to advantage 1-10 nm, the iron content is 70-99.9 wt. %, to advantage 90 wt. %, the modification agent content 0.1-30 wt. %, to advantage 10 wt. %.

The particles of size smaller than 2 nm with polydispersity index smaller than 1.1 can be obtained by a modified method of preparation.

Superparamagnetic nanoparticle probes according to the invention are prepared by pre-precipitation of colloidal Fe(OH)₃ by the treatment of aqueous 0.1-0.2M solution of Fe(III) salt, to advantage FeCl₃, with less than an equimolar amount of NH₄OH, at 21° C., under sonication, to which a solution of a Fe(II) salt, to advantage FeCl₂, is added in the mole ratio Fe(III)/Fe(II)=2 under sonication and the mixture is poured into five- to tenfold, to advantage eightfold, molar excess of 0.5M NH₄OH. The mixture is left aging for 0-30 min, to advantage 15 min, and then the precipitate is repeatedly, to advantage 7-10 times, magnetically separated and washed with deionized water. Then 1-3 fold amount, to advantage 1.5 fold amount, relative to the amount of magnetite, of 0.1 M aqueous solution of sodium citrate is added and then, dropwise, 1-3 fold amount, to advantage 1.5 fold amount, relative to the amount of magnetite, of 0.7 M aqueous solution of sodium hypochlorite. The precipitate is repeatedly, to advantage 7-10 times, washed with deionized water under the formation of colloidal maghemite to which, after dilution, is added dropwise, to advantage under 5-min sonication, an aqueous solution of a modification agent, in the weight ratio modification agent/iron oxide=0.1-10, to advantage 0.2 for amino acids and poly(amino acid)s and 5 for saccharides.

The particles smaller than 2 nm with polydispersity index smaller than 1.1 are prepared by mixing at 21° C. 1 volume part of 10-60 wt. %, to advantage 50 wt. %, of an aqueous solution of a saccharide, disaccharide or polysaccharide, such as D-arabinose, D-glucose, D-galactose, D-mannose, lactose, maltose, dextran and dextrins, and 1 volume part of aqueous solution of a Fe(II) and Fe(III) salt, to advantage FeCl₂ and FeCl₃, where the molar ratio Fe(III)/Fe(II)=2. A 5-15%, to advantage 7.5%, solution of NH₄OH is added until pH 12 is attained and the mixture is heated at 60° C. for 15 min. The mixture is then sonicated at 350 W for 5 min and then washed for 24 h by dialysis in water using a membrane with molecular weight cut-off 14,000 until pH 7 is reached. The volume of solution is reduced by evaporation so that the final dry matter content is 50-100 mg/ml, to advantage 80 mg per 1 ml.

Superparamagnetic nanoparticle probes according to the invention can be used for labelling cells used in magnetic resonance imaging for monitoring their movement, localization, survival and differentiation especially in detection of pathologies with cell dysfunction and of tissue regeneration and also for labelling and monitoring cells administered for cell therapy purposes, in particular embryonal stem cells, fetal stem cells, stem cells of an adult human including bone marrow stem cells, olfactory glial cells, fat tissue cells, in the recipient organism by magnetic resonance.

The preparation of labelled cells proceeds by adding to the complete culture medium 5-20 μl, to advantage 10 μl, of a colloid containing 0.05-45 mg iron oxide per ml, to advantage 1-5 mg iron oxide per ml of the medium, and culturing the cells for a period of 1-7 days, to advantage for 1-3 days, at 37° C. and 5% of CO₂.

A base-facilitated reaction for the production of hydrogen from biomass or component(s) thereof. Hydrogen is produced from a reaction of naturally occurring organic matter with a base to form a bicarbonate or carbonate compound as a by-product. The base-facilitated hydrogen-producing reactions are thermodynamically more spontaneous than conventional-type reformation reactions and are able to produce hydrogen gas at less extreme reaction conditions than conventional-type reformation reactions. The preferred reactants are biomass, components of biomass, and mixtures of components of biomass. Especially preferred are base-facilitated reactions in which hydrogen is produced from carbohydrates or mixtures of carbohydrates, include monosaccharides, disaccharides, polysaccharides, and cellulose. The instant reactions can occur in the liquid phase or solid.

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.